Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Interpace Biosciences

Nasdaq:IDXG
Snowflake Description

High growth potential with imperfect balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
IDXG
Nasdaq
$20M
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

Interpace Biosciences, Inc. develops and commercializes molecular diagnostic tests to detect genetic alterations associated with gastrointestinal, endocrine, and lung cancers. The last earnings update was 141 days ago. More info.


Add to Portfolio Compare Print
  • Interpace Biosciences has significant price volatility in the past 3 months.
IDXG Share Price and Events
7 Day Returns
-8.6%
NasdaqCM:IDXG
-4%
US Healthcare
-4.1%
US Market
1 Year Returns
-37.8%
NasdaqCM:IDXG
-4.6%
US Healthcare
-14.9%
US Market
IDXG Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Interpace Biosciences (IDXG) -8.6% -38.9% -6% -37.8% -77.9% -96.6%
US Healthcare -4% -12.9% -18.2% -4.6% 12.3% 13.1%
US Market -4.1% -19.1% -23.4% -14.9% 3.5% 14.5%
1 Year Return vs Industry and Market
  • IDXG underperformed the Healthcare industry which returned -4.6% over the past year.
  • IDXG underperformed the Market in United States of America which returned -14.9% over the past year.
Price Volatility
IDXG
Industry
5yr Volatility vs Market

Value

 Is Interpace Biosciences undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Interpace Biosciences. This is due to cash flow or dividend data being unavailable. The share price is $4.89.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Interpace Biosciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Interpace Biosciences's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:IDXG PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in USD $-5.77
NasdaqCM:IDXG Share Price ** NasdaqCM (2020-04-02) in USD $4.89
United States of America Healthcare Industry PE Ratio Median Figure of 45 Publicly-Listed Healthcare Companies 20.24x
United States of America Market PE Ratio Median Figure of 2,944 Publicly-Listed Companies 12.5x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Interpace Biosciences.

NasdaqCM:IDXG PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:IDXG Share Price ÷ EPS (both in USD)

= 4.89 ÷ -5.77

-0.85x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Interpace Biosciences is loss making, we can't compare its value to the US Healthcare industry average.
  • Interpace Biosciences is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Interpace Biosciences's expected growth come at a high price?
Raw Data
NasdaqCM:IDXG PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.85x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
59.6%per year
United States of America Healthcare Industry PEG Ratio Median Figure of 32 Publicly-Listed Healthcare Companies 1.52x
United States of America Market PEG Ratio Median Figure of 2,008 Publicly-Listed Companies 0.91x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Interpace Biosciences, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Interpace Biosciences's assets?
Raw Data
NasdaqCM:IDXG PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in USD $6.18
NasdaqCM:IDXG Share Price * NasdaqCM (2020-04-02) in USD $4.89
United States of America Healthcare Industry PB Ratio Median Figure of 94 Publicly-Listed Healthcare Companies 2.31x
United States of America Market PB Ratio Median Figure of 5,142 Publicly-Listed Companies 1.22x
NasdaqCM:IDXG PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:IDXG Share Price ÷ Book Value per Share (both in USD)

= 4.89 ÷ 6.18

0.79x

* Primary Listing of Interpace Biosciences.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Interpace Biosciences is good value based on assets compared to the US Healthcare industry average.
X
Value checks
We assess Interpace Biosciences's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check)
  5. Interpace Biosciences has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Interpace Biosciences expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
59.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Interpace Biosciences expected to grow at an attractive rate?
  • Interpace Biosciences's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • Interpace Biosciences's earnings growth is expected to exceed the United States of America market average.
  • Interpace Biosciences's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:IDXG Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:IDXG Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 59.6%
NasdaqCM:IDXG Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 32%
United States of America Healthcare Industry Earnings Growth Rate Market Cap Weighted Average 13.5%
United States of America Healthcare Industry Revenue Growth Rate Market Cap Weighted Average 6.6%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.2%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:IDXG Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:IDXG Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 184 71 1
2023-12-31 149 52 1
2022-12-31 101 22 2
2021-12-31 70 1 3
2020-12-31 52 -9 5
2020-04-03
2019-12-31 31 -20 5
NasdaqCM:IDXG Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-09-30 26 -14 -20
2019-06-30 24 -11 -16
2019-03-31 23 -9 -12
2018-12-31 22 -9 -12
2018-09-30 20 -9 -13
2018-06-30 19 -12 -13
2018-03-31 17 -14 -18
2017-12-31 16 -15 -13
2017-09-30 15 -14 -1
2017-06-30 14 -11 -5
2017-03-31 14 -8 -3
2016-12-31 13 -8 -8

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Interpace Biosciences's earnings are expected to grow significantly at over 20% yearly.
  • Interpace Biosciences's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:IDXG Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Interpace Biosciences Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:IDXG Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 9.70 9.70 9.70 1.00
2023-12-31 7.20 7.20 7.20 1.00
2022-12-31 3.10 5.20 1.00 2.00
2021-12-31 -0.90 2.20 -4.50 3.00
2020-12-31 -4.20 -1.50 -9.70 5.00
2020-04-03
2019-12-31 -5.00 -4.40 -5.40 5.00
NasdaqCM:IDXG Past Financials Data
Date (Data in USD Millions) EPS *
2019-09-30 -5.77
2019-06-30 -4.87
2019-03-31 -4.14
2018-12-31 -4.33
2018-09-30 -4.68
2018-06-30 -5.08
2018-03-31 -8.19
2017-12-31 -8.08
2017-09-30 -1.56
2017-06-30 -12.13
2017-03-31 -10.41
2016-12-31 -46.31

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Interpace Biosciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Interpace Biosciences's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Interpace Biosciences has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Interpace Biosciences performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Interpace Biosciences's growth in the last year to its industry (Healthcare).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Interpace Biosciences does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Interpace Biosciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Interpace Biosciences's 1-year growth to the US Healthcare industry average as it is not currently profitable.
Earnings and Revenue History
Interpace Biosciences's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Interpace Biosciences Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:IDXG Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 25.84 -20.21 22.72 2.63
2019-06-30 23.87 -15.84 19.61 2.28
2019-03-31 23.10 -12.42 18.08 2.15
2018-12-31 21.90 -12.21 16.92 2.12
2018-09-30 20.43 -12.98 18.40 1.79
2018-06-30 18.88 -13.36 18.20 1.76
2018-03-31 17.24 -17.74 17.23 1.66
2017-12-31 15.90 -12.74 17.22 1.46
2017-09-30 14.65 -1.48 15.06 1.51
2017-06-30 13.76 -5.29 15.27 1.69
2017-03-31 13.52 -2.55 15.76 1.63
2016-12-31 13.09 -8.41 15.97 1.65
2016-09-30 12.52 -23.22 19.13 1.99
2016-06-30 11.71 -23.49 20.36 2.33
2016-03-31 10.35 -28.09 23.38 2.38
2015-12-31 9.43 -31.07 24.58 2.29
2015-09-30 -82.75 -31.11 13.50 1.90
2015-06-30 -57.00 -26.93 15.05 0.90
2015-03-31 -28.24 -19.95 14.95 0.49
2014-12-31 1.47 -13.47 14.92 0.26
2014-09-30 123.21 -5.73 23.00
2014-06-30 129.21 -4.56 22.82
2014-03-31 135.44 -4.35 24.26
2013-12-31 146.53 -1.68 24.94
2013-09-30 150.06 -24.81 27.37
2013-06-30 147.58 -23.53 27.31

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Interpace Biosciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Interpace Biosciences has efficiently used its assets last year compared to the US Healthcare industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Interpace Biosciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Interpace Biosciences's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Interpace Biosciences has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Interpace Biosciences's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Interpace Biosciences's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Interpace Biosciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Interpace Biosciences's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Interpace Biosciences's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Interpace Biosciences Company Filings, last reported 6 months ago.

NasdaqCM:IDXG Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 36.76 10.57 2.36
2019-06-30 30.83 0.00 4.21
2019-03-31 35.77 0.00 9.12
2018-12-31 32.94 0.00 6.07
2018-09-30 36.03 0.00 8.00
2018-06-30 38.55 0.00 10.08
2018-03-31 39.77 0.00 12.65
2017-12-31 39.87 0.00 15.20
2017-09-30 36.38 0.00 11.70
2017-06-30 36.34 0.00 14.27
2017-03-31 24.57 4.36 7.13
2016-12-31 6.53 7.91 0.60
2016-09-30 -1.48 9.02 1.69
2016-06-30 5.99 8.81 3.04
2016-03-31 8.31 8.60 4.34
2015-12-31 13.04 8.40 8.42
2015-09-30 5.86 27.91 9.40
2015-06-30 10.30 27.69 15.03
2015-03-31 16.62 27.35 17.43
2014-12-31 20.12 27.15 23.75
2014-09-30 25.42 0.00 29.27
2014-06-30 29.35 0.00 38.53
2014-03-31 31.34 0.00 40.73
2013-12-31 32.48 0.00 49.10
2013-09-30 36.01 0.00 51.07
2013-06-30 37.72 0.00 53.34
  • Interpace Biosciences's level of debt (28.8%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (1.2% vs 28.8% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Interpace Biosciences has less than a year of cash runway based on current free cash flow.
  • Interpace Biosciences has less than a year of cash runway if free cash flow continues to reduce at historical rates of -7.8% each year.
X
Financial health checks
We assess Interpace Biosciences's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Interpace Biosciences has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Interpace Biosciences's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Interpace Biosciences dividends.
If you bought $2,000 of Interpace Biosciences shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Interpace Biosciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Interpace Biosciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:IDXG Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
United States of America Healthcare Industry Average Dividend Yield Market Cap Weighted Average of 20 Stocks 1.8%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1941 Stocks 3.1%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:IDXG Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-03
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Interpace Biosciences has not reported any payouts.
  • Unable to verify if Interpace Biosciences's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Interpace Biosciences's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Interpace Biosciences has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Interpace Biosciences's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Interpace Biosciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Interpace Biosciences has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Interpace Biosciences's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jack Stover
COMPENSATION $1,307,880
AGE 66
TENURE AS CEO 3.8 years
CEO Bio

Mr. Jack E. Stover, CPA has been the Chief Executive Officer and President of Interpace Diagnostics Group, Inc. since June 21, 2016. Mr. Stover has been Chief Executive Officer of Zebec Therapeutics LLC (Zebec) since September 2013. Zebec is the successor to Quadrant Pharmaceuticals LLC, which he co-founded and was President and Director since September 2013. Mr. Stover served as Interim Chief Executive Officer and President of Interpace Diagnostics Group, Inc. since December 22, 2015 until June 20, 2016. From 2009 to February 2012, he served as the Executive Chairman of Targeted Nano Therapeutics LLC from 2009 to February 2012. Mr. Stover served as the Chief Executive Officer at Antares Pharma Inc. from September 1, 2004 to October 2008. He served as Chief Operating Officer at Antares Pharma Inc., from July 2004 to September 1, 2004 and President from July 22, 2004 to July 2008. Prior to joining Antares Pharma, he served as Executive Vice President, Chief Financial Officer and Treasurer of SICOR Inc., from April 2002 to August 12, 2003. Prior to joining Sicor Inc., from 1993 to 1998, he served as Executive Vice President of proprietary women's drug company, Gynetics Inc.'s first private placement and other various merger and acquisition activities as Senior Vice President, Chief Information Officer and Chief Financial Officer of B. Braun Medical Inc. From 1998 to 2000, Mr. Stover served as Chief Operating and Financial Officer of Gynetics Inc. He was a Partner of Crawford Capital HealthTech Ventures II, L.P. and Crawford Capital. From 1975 to 1993, he was employed by PricewaterhouseCoopers LLP (formerly, Coopers & Lybrand), where since 1985, he was a Partner and delivered advisory services to medical and biotechnology clients. He was a Partner- in- Charge for Pricewaterhouse Coopers' LifeSciences Practice in New Jersey. From 2001 to 2002, Mr. Stover was a Venture Partner for Sarnoff Corp. He served as Vice Chairman of Antares Pharma Inc. until October 2008 and its Executive Director from September 1, 2004 to October 2008. He has been a Director of Onconova Therapeutics, Inc. since May 23, 2016. He has been a Director of Interpace Diagnostics Group, Inc. since August 9, 2005 and served as a Director of Cernostics, Inc. since March 2015 until July 2016. He has been a Director of Viatar CTC Solutions Inc. since July 1, 2016. He served as Director of B. Braun Medical Inc. and Gynetics Inc. From 2005 to 2015, he served as a Member of the board of directors at PDI Inc. He served as a Director at JE Stover Consulting, LLC from 2008 to 2015. He served as Director of Arbios Systems Inc., from 2005 to 2008 and Influmedix, Inc. from 2010 to 2011. Mr. Stover served as Director for several health care companies. Mr. Stover holds a B.S. in Accounting and Business from Lehigh University in 1975 and is a licensed Certified Public Accountant.

CEO Compensation
  • Jack's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Jack's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Interpace Biosciences management team in years:

2.1
Average Tenure
55
Average Age
  • The tenure for the Interpace Biosciences management team is about average.
Management Team

Jack Stover

TITLE
CEO, President & Director
COMPENSATION
$1M
AGE
66
TENURE
3.8 yrs

Greg Richard

TITLE
Senior VP & Chief Commercial Officer
COMPENSATION
$619K
AGE
52
TENURE
6 yrs

Fred Knechtel

TITLE
CFO, Treasurer & Company Secretary
AGE
58
TENURE
0.3 yrs

Glenn Gershon

TITLE
Senior Vice President of Operations

Thomas Freeburg

TITLE
Chief Accounting Officer
AGE
51
TENURE
2.1 yrs

Sydney Finkelstein

TITLE
Chief Scientific Officer

Alidad Mireskandari

TITLE
Senior Vice President of Business Development
TENURE
0.3 yrs

Glenn Miles

TITLE
Chief Financial Officer of Interpace Pharma Solutions
TENURE
0.3 yrs

Patrick Kane

TITLE
VP & Corporate Controller
TENURE
10.8 yrs
Board of Directors Tenure

Average tenure and age of the Interpace Biosciences board of directors in years:

0.8
Average Tenure
65.5
Average Age
  • The average tenure for the Interpace Biosciences board of directors is less than 3 years, this suggests a new board.
Board of Directors

Steve Sullivan

TITLE
Independent Chairman of the Board
COMPENSATION
$87K
AGE
72
TENURE
4.3 yrs

Jack Stover

TITLE
CEO, President & Director
COMPENSATION
$1M
AGE
66
TENURE
14.7 yrs

Joe Keegan

TITLE
Independent Director
COMPENSATION
$77K
AGE
65
TENURE
4.3 yrs

Eric Lev

TITLE
Director
TENURE
0.8 yrs

Robert Gorman

TITLE
Independent Director
TENURE
0.5 yrs

Edward Chan

TITLE
Director
TENURE
0.3 yrs

Ron Rocca

TITLE
Independent Director
AGE
58
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Interpace Biosciences's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Interpace Biosciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Did Changing Sentiment Drive Interpace Diagnostics Group's (NASDAQ:IDXG) Share Price Down A Disastrous 98%?

View our latest analysis for Interpace Diagnostics Group Because Interpace Diagnostics Group is loss-making, we think the market is probably more focussed on revenue and revenue growth, at least for now. … Over half a decade Interpace Diagnostics Group reduced its trailing twelve month revenue by 25% for each year. … A Different Perspective Investors in Interpace Diagnostics Group had a tough year, with a total loss of 19%, against a market gain of about 7.2%.

Simply Wall St -

If You Had Bought Interpace Diagnostics Group (NASDAQ:IDXG) Stock Five Years Ago, You'd Be Sitting On A 98% Loss, Today

See our latest analysis for Interpace Diagnostics Group Because Interpace Diagnostics Group is loss-making, we think the market is probably more focussed on revenue and revenue growth, at least for now. … Over half a decade Interpace Diagnostics Group reduced its trailing twelve month revenue by 25% for each year. … You could get a better understanding of Interpace Diagnostics Group's growth by checking out this more detailed historical graph of earnings, revenue and cash flow.

Simply Wall St -

Here's What We Think About Interpace Diagnostics Group, Inc.'s (NASDAQ:IDXG) CEO Pay

Check out our latest analysis for Interpace Diagnostics Group How Does Jack Stover's Compensation Compare With Similar Sized Companies? … We compared the total CEO remuneration paid by Interpace Diagnostics Group, Inc., and compared it to remuneration at a group of similar sized companies. … If you think CEO compensation levels are interesting you will probably really like this free visualization of insider trading at Interpace Diagnostics Group.

Simply Wall St -

Interpace Diagnostics Group, Inc. (NASDAQ:IDXG): Are Analysts Optimistic?

Interpace Diagnostics Group, Inc.'s (NASDAQ:IDXG):. … Interpace Diagnostics Group, Inc. … See our latest analysis for Interpace Diagnostics Group

Simply Wall St -

Do Directors Own Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) Shares?

If you want to know who really controls Interpace Diagnostics Group, Inc. … Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … Interpace Diagnostics Group is not a large company by global standards.

Simply Wall St -

Those Who Purchased Interpace Diagnostics Group Shares Five Years Ago Have A 98% Loss To Show For It

Because Interpace Diagnostics Group is loss-making, we think the market is probably more focussed on revenue and revenue growth, at least for now. … When a company doesn't yet make profits, we'd generally expect to see good revenue growth. … Over half a decade Interpace Diagnostics Group reduced its trailing twelve month revenue by 45% for each year.

Simply Wall St -

Are Interpace Diagnostics Group, Inc.'s (NASDAQ:IDXG) Interest Costs Too High?

However, it also faces higher cost of capital given interest cost is generally lower than equity. … Does IDXG's growth rate justify its decision for financial flexibility over lower cost of capital … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital.

Simply Wall St -

Is Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) Overpaying Its CEO?

First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Jack Stover's Compensation Compare With Similar Sized Companies. … has a market cap of US$25m, and is paying total annual CEO compensation of US$2.1m.

Simply Wall St -

What Kind Of Shareholders Own Interpace Diagnostics Group Inc (NASDAQ:IDXG)?

If you want to know who really controls Interpace Diagnostics Group Inc (NASDAQ:IDXG), then you'll have to look at the makeup of its share registry. … Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. … Interpace Diagnostics Group is a smaller company with a market capitalization of US$29m, so it may still be flying under the radar of many institutional investors.

Simply Wall St -

Analysts Expect Breakeven For Interpace Diagnostics Group Inc (NASDAQ:IDXG)

Interpace Diagnostics Group Inc's (NASDAQ:IDXG):. … Interpace Diagnostics Group, Inc. … With the latest financial year loss of -US$13m and a trailing-twelve month of -US$13m, the US$39m market-cap amplifies its loss by moving further away from its breakeven target?

Simply Wall St -

Company Info

Description

Interpace Biosciences, Inc. develops and commercializes molecular diagnostic tests to detect genetic alterations associated with gastrointestinal, endocrine, and lung cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinderTG platform; ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules; ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules; and RespriDx, a genomic test to differentiate metastatic or recurrent lung cancer. The company also provides pathology services. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

Details
Name: Interpace Biosciences, Inc.
IDXG
Exchange: NasdaqCM
Founded: 1986
$19,528,821
3,993,624
Website: http://www.interpace.com
Address: Interpace Biosciences, Inc.
Morris Corporate Center 1,
Building C,
Parsippany,
New Jersey, 07054,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM IDXG Common Stock Nasdaq Capital Market US USD 20. May 1998
DB PF41 Common Stock Deutsche Boerse AG DE EUR 20. May 1998
Number of employees
Current staff
Staff numbers
89
Interpace Biosciences employees.
Industry
Health Care Services
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/03 05:22
End of day share price update: 2020/04/02 00:00
Last estimates confirmation: 2020/03/11
Last earnings filing: 2019/11/14
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.